Skip to content
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity
Home
About US
Bioinsight
Policy Hub
Deals Book
Privacy Policy
Contact US
Hualan Biological
Home
Hualan Biological
You Missed
Company
Deals
Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
Company
Drug
Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
Company
Drug
Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
Company
Drug
Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
Search for: